A beta blocker typically used to treat heart problems, hemangioma, migraines and anxiety could be a new therapeutic for patients with sickle cell disease.
A beta blocker typically used to treat heart problems, hemangioma, migraines and anxiety could be a new therapeutic for patients with sickle cell disease. Researchers led by Ankit A. Desai, MD, associate professor of medicine at the Krannert Cardiovascular Research Center (KCVRC) at Indiana University School of Medicine, have been awarded a $3 million grant by the U.S. Department of Defense to evaluate the efficacy of this drug.
In a consensus statement, the Canadian Cardiovascular Society defines four stages of acute atherothrombotic myocardial infarction based on tissue injury severity.
The Canadian Cardiovascular Society (CCS) released the world's first classification of acute myocardial infarction (AMI), or heart attack, based on heart tissue damage research that was driven by two cardiovascular investigators within the Ischemic Heart Disease Program of Krannert Cardiovascular Research Center (KCVRC) at Indiana University School of Medicine and Northern Ontario School of Medicine.